Success Metrics

Completion Rate
0%(0/2)
Active Trials
3(43%)
Terminated
2(29%)

Phase Distribution

Ph phase_1
2
29%
Ph phase_2
5
71%

Phase Distribution

2

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
5(71.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 4 finished

Non-Completion Rate

100.0%

4 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(3)
Terminated(4)

Detailed Status

Recruiting3
Terminated2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (28.6%)
Phase 25 (71.4%)

Trials by Status

recruiting343%
terminated229%
withdrawn229%

Recent Activity

3 active trials
Showing 5 of 7
recruitingphase_2

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

NCT04253964
recruitingphase_2

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features

NCT06449313
recruitingphase_1

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

NCT04975152
terminatedphase_2

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

NCT04006119
withdrawnphase_1

Cemiplimab/Peg-Interferon-α in Advanced CSCC

NCT05729139
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04253964Phase 2

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Recruiting
NCT06449313Phase 2

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features

Recruiting
NCT04975152Phase 1

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Recruiting
NCT04006119Phase 2

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

Terminated
NCT05729139Phase 1

Cemiplimab/Peg-Interferon-α in Advanced CSCC

Withdrawn
NCT04242173Phase 2

Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

Terminated
NCT04831450Phase 2

Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)

Withdrawn

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7